Update on the role of Toll-like receptors during bacterial infections and sepsis

Wiener Medizinische Wochenschrift

Volumn 160, Issue 5-6, 2010, Pages 107-111

  Knapp, Sylvia ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bacterial infection; Innate immune system; Sepsis; Toll like receptors

Indexed keywords

DROTRECOGIN; ERITORAN; INTERLEUKIN 1; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 6; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN FUNCTION; ANTIGEN RECOGNITION; BACTERIAL INFECTION; BACTERIAL VIRULENCE; CLINICAL TRIAL; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; IMMUNOPATHOGENESIS; INFECTION SENSITIVITY; INFLAMMATION; INNATE IMMUNITY; LIGAND BINDING; NONHUMAN; REVIEW; SEPSIS; SEPTIC SHOCK; SURVIVAL TIME; SYSTEMIC DISEASE;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL INFECTIONS; HUMANS; IMMUNITY, INNATE; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; MICE; NEUTROPHILS; SEPSIS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77952503608     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10354-010-0765-6     Document Type: Review

References (41)

1. Medzhitov R, Janeway C, Jr. Innate immunity. N Engl J Med, 343: 338-344.
2. Takeda K, Kaisho T, Akira S. Toll-Like Receptors. Annu Rev Immunol, 9: 9, 2003.
3. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol, 1: 135-145, 2001.
4. Barton GM, Kagan JC. A cell biological view of Toll-like receptor function: regulation through compartmentalization. Nat Rev Immunol, 9: 535-542, 2009.
5. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/ HeJ and C57BL/10ScCr mice: mutations in TLR4 gene. Science, 282: 2085-2088, 1998.
6. Qureshi ST, Lariviere L, Leveque G, et al. Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (TLR4). J Exp Med, 189: 615-625, 1999.
7. Hoshino K, Takeuchi O, Kawai T, et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol, 162: 3749-3752, 1999.
8. van Westerloo DJ, Weijer S, Bruno MJ, et al. Toll-like receptor 4 deficiency and acute pancreatitis act similarly in reducing host defense during murine Escherichia coli peritonitis. Crit Care Med, 33: 1036-1043, 2005.
9. Knapp S, Wieland CW, Florquin S, et al. Differential roles of CD14 and Toll-like receptors 4 and 2 in murine acinetobacter pneumonia. Am J Resp Crit Care Med, 173: 122-129, 2006.
10. Branger J, Knapp S, Weijer S, et al. Role of Toll-like receptor 4 in Gram-positive and Gram-negative pneumonia in mice. Infect Immun, 72: 788-794, 2004. (Pubitemid 38166657)
11. Shimazu R, Akashi S, Ogata H, et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med, 189: 1777-1782, 1999.
12. Visintin A, Mazzoni A, Spitzer JA, et al. Secreted MD-2 is a large polymeric protein that efficiently confers lipopolysaccharide sensitivity to Toll-like receptor 4. Proc Natl Acad Sci USA, 98: 12156-12161, 2001.
13. Nagai Y, Akashi S, Nagafuku M, et al. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol, 3: 667-672, 2002.
14. Pugin J, Stern-Voeffray S, Daubeuf B, et al. Soluble MD-2 activity in plasma from patients with severe sepsis and septic shock. Blood, 104: 4071-4079, 2004.
15. Takeuchi O, Hoshino K, Kawai T, et al. Differential roles of TLR2 and TLR4 in recognition of Gram-negative and Gram-positive bacterial cell wall components. Immunity, 11: 443-451, 1999.
16. Knapp S, von Aulock S, Leendertse M, et al. Lipoteichoic acidinduced lung inflammation depends on TLR2 and the concerted action of TLR4 and the platelet-activating factor receptor. J Immunol, 180: 3478-3484, 2008.
17. Takeuchi O, Hoshino K, Akira S. Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection. J Immunol, 165: 5392-5396, 2000.
18. Knapp S, Wieland CW, van .t Veer C, et al. Toll-like receptor 2 plays a role in the early inflammatory response to murine pneumococcal pneumonia but does not contribute to antibacterial defense. J Immunol, 172: 3132-3138, 2004.
19. Malley R, Henneke P, Morse SC, et al. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci USA, 100: 1966-1971, 2003.
20. Dessing MC, Florquin S, Paton JC, et al. Toll-like receptor 2 contributes to antibacterial defence against pneumolysin-deficient pneumococci. Cell Microbiol, 10: 237-246, 2008.
21. Skerrett SJ, Wilson CB, Liggitt HD, et al. Redundant Toll-like receptor signaling in the pulmonary host response to Pseudomonas aeruginosa. Am J Physiol Lung Cell Mol Physiol, 292: L312-L322, 2007.
22. Blohmke CJ, Victor RE, Hirschfeld AF, et al. Innate immunity mediated by TLR5 as a novel antiinflammatory target for cystic fibrosis lung disease. J Immunol, 180: 7764-7773, 2008.
23. Miyake K. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol, 19: 3-10, 2007.
24. Vogl T, Tenbrock K, Ludwig S, et al. Mrp8 andMrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med, 13: 1042-1049, 2007.
25. van Zoelen MA, Vogl T, Foell D, et al. Expression and role of myeloidrelated protein-14 in clinical and experimental sepsis. American journal of respiratory and critical care medicine, 180: 1098-1106, 2009.
26. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med, 36: 296-327, 2008.
27. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med, 344: 699-709, 2001.
28. Levi M, van der Poll T. Recombinant human activated protein C: current insights into its mechanism of action. Crit Care (London, England), Suppl 5: S3, 2007.
29. Gentry CA, Gross KB, Sud B, et al. Adverse outcomes associated with the use of drotrecogin alfa (activated) in patients with severe sepsis and baseline bleeding precautions. Crit Care Med, 37: 19-25, 2009.
30. Ferrer R, Artigas A, Suarez D, et al. Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. Am J Resp Crit Care Med, 180: 861-866, 2009.
31. O Neill LA, Bryant CE, Doyle SL. Therapeutic targeting of toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev, 61: 177-197, 2009.
32. Jiang D, Liang J, Fan J, et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med, 11: 1173-1179, 2005.
33. Park JS, Svetkauskaite D, He Q, et al. Involvement of Toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem, 279: 7370-7377, 2004.
34. Schaefer L, Babelova A, Kiss E, et al. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest, 115: 2223-2233, 2005.
35. Lai Y, Di Nardo A, Nakatsuji T, et al. Commensal bacteria regulate Toll-like receptor 3-dependent inflammation after skin injury. Nat Med, 15: 1377-1382, 2009.
36. Fabia B, Olivier S, Renate EG, et al. RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. Arthritis Riheum, 52: 2656-2665, 2005.
37. Okamura Y, Watari M, Jerud ES, et al. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem, 276: 10229-10233, 2001.
38. Imai Y, Kuba K, Neely GG, et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell, 133: 235-249, 2008.
39. Vollmer J, Tluk S, Schmitz C, et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Tolllike receptors 7 and 8. J Exp Med, 202: 1575-1585, 2005.
40. Tian J, Avalos AM, Mao S-Y, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol, 8: 487-496, 2007.
41. Leadbetter EA, Rifkin IR, Hohlbaum AM, et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature, 416: 603-607, 2002.